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SOMMARIO 
 
INTRODUZIONE: I gliomi costituiscono i tumori maligni più comuni e letali del 
sistema nervoso centrale e rappresentano l'1,3% di tutti i tumori umani. 
I Glioblastoma (GBM, WHO IV grado) sono la neoplasia cerebrale di derivazione 
astrocitaria,  più frequente negli adulti, in particolar modo nei pazienti anziani con 
età media di 55 anni. Essi sono caratterizzati da un comportamento altamente 
aggressivo e da prognosi infausta, con un’aspettativa di vita non superiore ai 14 
mesi. Negli ultimi anni, l’assenza di opzioni terapeutiche adeguate ha spinto la 
comunità scientifica a ricercare differenti bersagli molecolari e bio-marcatori in 
grado di permettere una più adeguata stratificazione prognostica e terapeutica dei 
pazienti. Infatti, l'assenza di opzioni terapeutiche adeguate rendono i GBM una 
malattia mortale. 
I gliomi sono caratterizzati dalla presenza di focolai necrotici circondati da cellule 
ipossiche. Questo microambiente sfavorevole suscita nelle cellule tumorali percorsi 
di compensazione come l’autofagia e la risposta a proteine con un errato 
ripiegamento spaziale (UPR). Essi sono due percorsi interconnessi e sfruttati dalle 
cellule tumorali per far fronte a condizioni di scarsità di nutrienti, ipossia o stress 
generato all’interno del microambiente neoplastico. Inoltre, è stato dimostrato come 
l’ipossia sia essenziale per la motilità cellulare e per la salvaguardia della 
cosiddetta nicchia di cellule staminali tumorali (GSC). 
Le proteine dello shock termico (HSP) sono proteine altamente conservate, che 
vengono espresse in risposta a varie forme di stress e a cambiamenti ambientali, e  
in specifici stadi di sviluppo e differenziazione. Alcune di esse sono espresse 
anche in condizioni  fisiologiche agendo da chaperon molecolari. Le HSP, quindi, 
compiono una varietà di funzioni biologiche, tra cui la regolazione della sintesi, 
piegatura, assemblaggio, e degradazione di differenti tipi di proteine. Inoltre, esse 
sono costitutivamente espresse in numerosi tipi di neoplasie ed in linee cellulari 
tumorali di diversa origine istogenetica. Lo chaperon GRP78, situato nel reticolo 
endoplasmatico, è anch’esso espresso in maniera aberrante in differenti tipi di 
tumori umani, e studi  preliminari hanno dimostrato che la sua inibizione in modelli 
animali di glioma è in grado di ritardare la crescita neoplastica.  
L'elevata espressione delle HSP nel glioma maligno potrebbe indicare un possibile 
coinvolgimento di queste proteine nella resistenza alla chemioterapia. Esse infatti, 
svolgono un ruolo di protezione all’interno delle cellule da agenti o condizioni di 
stress ambientale in grado di danneggiarle. 
SCOPO DELLO STUDIO: Valutare la relazione tra l'espressione dell’asse HSP90-
GRP78, nelle aree peri-necrotiche tumorali e/o nelle cellule a pseudo-palizzata, 
contribuisce a mantenere un ambiente favorevole alla sopravvivenza e se essa è 
regolata da stimoli ipossici che svolgono un ruolo nel sostenere le cellule staminali 
di glioma e la motilità cellulare. Definire il contributo degli chaperon molecolari nella 
modulazione da parte di farmaci specifici sull’assetto HSP-GRP78 per fornire 
targets per nuove terapie utili per migliorare la prognosi dei pazienti affetti da 
tumori cerebrali. 
MATERIALI E METODI: Casistica Clinica. E’ stata raccolta una larga coorte di 
pazienti (n° 123), reclutati presso la Fondazione IRCCS Ca' Granda tra il 2013 e il 
2016, con profili molecolari e caratteristiche clinico-patologiche associate. Da 
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ciascun paziente è stato isolato l'RNA totale con Tizol® reagent (Thermo Fisher 
Scientific). Per la quantificazione dell'espressione genica sono stati utilizzati 
reagenti HumanTaqManAssays (Applied Biosystems). Linee cellulari di glioma. 
LN229, SW1088 e T98G provenienti dall’ATCC sono state mantenute come 
suggerito dal produttore. Le cellule U251-HRE sono state donate dalla Dott.ssa 
Ottobrini. Sono stati effettuati esperimenti di gene knock-out. Trasfezioni transienti 
di short interfering RNA (Sigma Aldrich) sono state effettuate utilizzando 
Lipofectamine3000 (Life Technologies). Colture tissutali organotipiche. Colture 
organotipiche di glioma sono state ottenute attraverso l’utilizzo del vibratome 
(VT1200 Leica Microsystems). Le fettine sono state coltivate su supporti dedicati 
(Millipore), in presenza o assenza di farmaci: Temozolomide e/o Gamitrinibs. 
RISULTATI: L'espressione di GRP78 e di TRAP1 appare aumentata nei tumori di 
alto grado rispetto a quelli di basso grado o al parenchima cerebrale normale. 
Elevati livelli di proteina correlano a prognosi infausta.  
Inoltre, GRP78 sembra essere arricchito nelle aree peri-necrotiche dei gliomi 
umani ad alto grado e la sua overespressione correla con HIF-1α. Modulando 
l’espressione di GRP78 in linee cellulari LN229, tramite siRNA o trattamento 
farmacologico con Gamitrinibs, si ottiene una diminuzione della popolazione side e 
della motilità delle cellule tumorali. Il regolatore di ipossia HIF1α diminuisce in 
cellule knock-out per TRAP1 rispetto al controllo, e un aumento dei geni 
dell’apoptosi si evidenzia dopo trattamento farmacologico. Infine il trattamento con 
Gamitrinibs, rispetto alla Temozolomide, influenza significativamente la vitalità 
tumorale in colture organotipiche di glioma. 
CONCLUSIONI: Questi dati suggeriscono che GRP78 rappresenta un marker 
prognostico negativo per i gliomi di alto grado, e che le HSPs sono arricchite nelle 
aree tumorali peri-necrotiche dove sostengono un ambiente pro-sopravvivenza. 
Inoltre, la sovra-espressione di GRP78 nei tumori cerebrali potrebbe preservare la 
popolazione di cellule staminali in condizioni di stress, come l’ipossia. Questo 
studio sembra confermare il potenziale ruolo di GRP78 come bersaglio molecolare 
nel trattamento del glioma maligno. 
PAROLE CHIAVE: GBM, Ipossia, GSC, HSPs, GRP78, HSP90 
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ABSTRACT 
 
INTRODUCTION: Gliomas are the most common and lethal malignant tumor of the 
central nervous system representing 1.3% of all human cancers. Glioblastoma 
(GBM, WHO grade IV) is the most common astrocytic-derived brain tumor in 
adults, more frequent in older patients (mean age 55 years). They are 
characterized by a highly aggressive behavior and poor prognosis. Survival rates 
for gliomas are poor with a median survival that is not exceeding 14 months.  
Over the last years, the absence of adequate therapeutic options has led the 
scientific community to seek different molecular targets and bio-markers able to 
allow a more adequate prognostic and therapeutic stratification of patients. In fact, 
the absence of adequate therapeutic options makes GBM a fatal disease. 
A feature of gliomas is the presence of tumor necrotic foci surrounded by severely 
hypoxic pseudopalisading cells. This unfavorable microenvironment elicits in tumor 
cells compensatory pathways as autophagy and the unfolded-protein response 
(UPR). They are two interconnected pathways exploited by tumor cells to cope with 
low nutrient conditions, hypoxia or other microenvironment-generated stress. 
Moreover, evidences showed that tumor hypoxia fuel cell motility and preserve the 
so-called cancer stem cells niche (CSCs).  
Heat shock proteins (HSPs) are highly conserved proteins which are expressed in 
response to various forms of stress, in response to environmental challenges, and 
in specific stages of development and differentiation. Some HSPs are also 
expressed under non stress conditions and act as molecular chaperones. Thus, 
HSPs fulfill a variety of biologic functions, including the regulation of synthesis, 
folding, assembly, and degradation of different proteins. HSPs are constitutively 
expressed in human carcinomas or cancer cell lines of various histogenetic origins. 
The endoplasmic reticulum chaperone GRP78 is aberrantly overexpressed by 
human cancers and preliminary reports showed that targeting of GRP78 in glioma 
animal model can delay cancer growth. The high expression of HSPs in malignant 
glioma indicates a possible role of these proteins in resistance to cancer 
chemotherapy. They in fact, protect cells from many cell-damaging agents or 
conditions of environmental stress.  
AIM OF THE STUDY: Assess whether the HSP90-GRP78 axe expression in peri-
necrotic tumor areas and/or pseudo-palisading cells contributes in maintaining a 
pro-survival environment and whether it is regulated by hypoxic stimuli, plays roles 
in glioma cancer stem cell maintenance and in glioma cell motility.  
Define the contribution of molecular chaperones in glioma modulation of HSP-
GRP78 axe by specific drugs to provide targets for novel therapies useful to 
improve prognosis of patients affected by brain tumors. 
MATERIALS AND METHODS: Clinical series. A series of patients’ (n° 123) 
recruited at IRCCS Ca’ Granda between 2013-2016, with correlation of molecular 
profiles to clinicopathological characteristic were collected. From each patient the 
total RNA was isolated with Tizol® reagent (Thermo Fisher Scientific). For gene 
expression quantification Human TaqManAssays (Applied Biosystems) and 
reagents were used. Glioma cell lines. LN229, SW1088 and T98G were from 
ATCC and maintained as suggested by manufacturer. U251-HRE cell were a 
generous gift from Dr. Ottobrini. Gene knock-out experiments were carried out as 
IV 
 
transient transfection of short interfering RNA (Sigma Aldrich) using 
Lipofectamine3000 as transfection reagent (LifeTechnologies). Organotypic tissue 
cultures. Organotypic glioma tissue were generated through vibratome (VT1200 
Leica Microsystems) serial cutting of fresh tumors, and slices were cultured on 
dedicated supports from Millipore, were cultured with or without the drugs: 
Temozolomide and/or Gamitrinibs. 
RESULTS: The expression of GRP78 and TRAP1 are increased in high-grade 
compared to lower grade or normal brain parenchyma and, high protein levels 
correlated to poor prognosis. Moreover, GRP78 appears to be enriched in peri-
necrotic areas of high-grade human gliomas where GRP78 overexpression 
correlates with HIF-1α expression. GRP78 targeting by siRNA or Gamitrinibs 
decreased the side population of LN229 cells as well as tumor cell motility. The 
hypoxia regulator HIF1α was decreased in TRAP1 knock-out cells respect to 
control. Lastly, an increase in apoptosis gene was evidenced after treatment with 
drugs. Finally, Gamitrinibs treatment of glioma organotypic cultures significantly 
affected tumor cell viability respect to Temozolomide. 
CONCLUSIONS: These data suggest that GRP78 is a poor prognostic marker for 
high grades gliomas and HSPs are enriched in peri-necrotic tumor areas sustaining 
a pro-survival environment. Moreover, these data suggest that GRP78 over-
expression in brain tumors could sustain the stem cell population in stress 
conditions such as hypoxia. This study confirms the potential role of GRP78 as a 
molecular target in the treatment of malignant glioma. 
KEY WORDS: GBM, Hypoxia, GSCs, HSPs, GRP78, HSP90 
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1. INTRODUCTION 
1.1 Brain tumors  
The 2016 World Health Organization (WHO) Classification of Tumors of 
Central Nervous System, for the first time uses molecular parameters in 
addition to histology to define many tumor entities, thus formulating a 
concept for how CNS tumor diagnoses should be structured in the 
molecular era. Most notably, in the past all astrocytic tumors had been 
grouped together. The 2007 WHO divides the diffuse gliomas into three 
main categories: astrocytomas (related to astrocytes), oligodendrogliomas 
(related to oligodendrocytes) and oligoastrocytomas (related to a mixture of 
these two cell types) [1]. Now all diffusely infiltrating gliomas (whether 
astrocytic or oligodendroglial) are grouped together: based not only on their 
growth pattern and behaviours, but also distinguishing on the entity of 
isocitrate dehydrogenase (IDH1 or IDH2) mutation and co-deletion of 
chromosomal arms 1p and 19q (Table 1) [2].      
The use of “integrated” phenotypic and genotypic parameters for CNS 
tumor classification adds a level of objectivity that has been missing from 
some aspects of the diagnostic process in the past [3]. It is hoped that this 
additional objectivity will yield more biologically homogeneous and narrowly 
defined diagnostic entities than in prior classifications, which in turn should 
lead to greater diagnostic accuracy as well as improved patient 
management and more accurate determinations of prognosis and treatment 
response. Nevertheless, WHO grade determinations are still made on the 
basis of histologic criteria. The phenotype remains essential is that because 
there are individual tumors that do not meet the more narrowly defined 
phenotype and genotype criteria. Combining histopathological and 
molecular features with the grade is show in table 2.  
The grade II diffuse astrocytomas, the grade III anaplastic astrocytomas 
and the grade IV glioblastomas are now each divided into IDH-mutant, IDH-
wildtype and NOS (not otherwise specified) categories. The diagnosis of 
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oligodendroglioma and anaplastic oligodendroglioma requires the 
demonstration of both an IDH gene family mutation and combined whole-
arm losses of 1p and 19q (1p/19q codeletion) (Figure 1). 
 
 
 
Table 1. The 2016 World Health Organization Classification of Tumors of 
               the Central Nervous System 
 
 
 
 
 
4 
 
 
 
Table 2. Grading of selected CNS tumors according to the 2016 CNS WHO 
 
 
 
Figure 1. Algorithm for classification of the diffuse gliomas based on     
                histological and genetic features 
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1.1.2 Epidemiology of gliomas  
Malignant brain and CNS tumors are the 17th most common cancer and 
the 3rd most common cause of cancer death with more than 250.000 new 
cases diagnosed annually. 
The worldwide incidence rate of primary malignant brain and CNS tumors 
in 2012, age-adjusted using the world standard population, was 3.4 per 
100,000 [4]. 
Gliomas are the most common primary tumors of the central nervous 
system, they account for the 77% of primary malignant brain tumors [5].                                                              
Individuals of all ages can be afflicted but the incidence rates of glioma 
dramatically increases with advancing age with a peak around 50-55 years. 
Overall, 42.1% of all tumors diagnosed between 2008 and 2012 occurred in 
males and 57.9% in females but the malignant tumors occurred higher in 
males (55%) than  in females (45%) (Figure 2) [6]. Furthermore, the 
incidence is 2-3 times higher in white than in black people [7]. Prognosis is 
poor and the median survival is 14.6 months; only few patients survive for 
three or more years. Infact, the survival after diagnosis with a primary 
malignant tumor in the US varies significantly by age, histology and 
behaviour Five-year relative survival rates following diagnosis of a primary 
malignant brain and CNS tumours 34.4% [8]. 
No underlying cause has been identified for the majority of malignant 
gliomas. The only established risk factor is exposure to ionizing radiation 
[9]. Approximately 5% of patients with malignant gliomas have a family 
history of gliomas. Some of these familial cases are associated with rare 
genetic syndromes, such as neurofibromatosis types 1 and 2, the 
Li−Fraumeni syndrome and Turcot's syndrome [10]. 
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Figure 2. Epidemiology of gliomas in the world divided by the sexes 
 
 
1.1.3 Glioma diagnosis  
Patients with a malignant glioma may present either focal or generalized  
neurologic symptoms, including headache, confusion and loss of memory, 
neurological deficits and personality changes. Generalized symptoms 
reflect increased intracranial pressure and consist of headache, vomiting, 
and a cranial-nerve palsies. Focal symptoms and signs, such as 
hemiparesis and aphasia, reflect the intracranial location of the tumor. 
When a brain tumors is clinically suspected, the only test needed to 
diagnose a brain tumor is cranial resonance magnetic imaging (MRI), with 
or without gadolinium infusion. Computed Tomography (CT) is appropriate 
as a first-line procedure to obtain a quick assessment of the lesion, 
although is less sensitive than MRI. The diagnosis is must be confirmed by 
histological examination of tumour biopsy sample or by surgical resection. 
These imaging studies typically show a heterogeneously enhancing mass 
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with surrounding edema. Glioblastoma (GBM) frequently have central areas 
of necrosis and more extensive peritumoral edema [11–13]. 
 
1.1.4 Glioma prognosis 
Despite decades of research and clinical trials, life expectancy for glioma 
patients has not improved considerably and is only about 2-3 years for 
anaplastic astrocytoma and 15 months for GBM [14,15]. 
There are several reasons because it has been so difficult to find new 
effective therapies against glioma. Drug delivery is limited by the blood-
brain-barrier impediment and the distorted glioma vessels [16]. 
The invasive nature of gliomas makes the complete surgical resection of 
the tumor impossible. Tumor cells also have a strong intrinsic attitude for 
malignant progression and some cells, supposedly the cancer stem cells, 
are resistant to therapy. Lastly, over-expression of proteins involved in DNA 
repair machinery could dampen the effects of radio- and chemotherapy 
[17]. 
 
1.1.5 Glioma treatment 
The standard treatment for gliomas is the surgical resection, radiotherapy 
and chemotherapy using alkylating agents. The size and localization of the 
tumor is important for the possibility to perform optimal surgery. Due to their 
invasive growth, gliomas indeed are impossible to completely resect. 
Surgery remains an important component in the treatment of GBM. It allows 
for a histologic confirmation of the diagnosis as well as cytoreduction. It 
may also serve a therapeutic role by reducing the intracranial pressure or to 
recovery of some neurological function. Advances in surgical imaging 
techniques, such as intraoperative magnetic resonance imaging (MRI), 
diffusion tensor imaging, awake craniotomy, cortical mapping, stereotactic 
guidance, and fluorescent-guided resection, have facilitated delineation of 
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tumor borders and have increased the extent of resection that can be 
achieved, improving  the safety of surgery [18–21]. 
The combination of radiotherapy (RT) plus chemotherapy (CHT) is the most 
efficacious adjuvant therapy to prolong survival after primary resection. 
Temozolomide (TMZ), an oral alkylating chemotherapeutic agent, causes 
DNA damage and triggers a cascade of events leading to tumor cell 
apoptosis. The combination of RT and TMZ, as compared with radiotherapy 
alone, prolonged the median survival (14.6 months versus 12.1 months) 
[14]. 
TMZ adding a methyl group to purine bases of DNA, which leads to DNA 
damage and triggers a cascade of events that leads to tumor cell apoptosis 
[22,23]. The primary cytotoxic target of TMZ is O6-methylguanine. The 
methyl group added to O6-methylguanine can be removed by O6-
methylguanine methyltransferase (MGMT), which is a DNA repair protein 
that functions to remove methyl groups from the O6 position of guanine. 
Removal of this methyl group confers resistance of tumor cells to TMZ and 
other alkylating chemotherapeutic agents by protecting cells from their 
DNA-damaging effects. In some patients, MGMT expression has been 
decreased or silenced by methylation of the promoter regions of the MGMT 
gene, preventing it from removing methyl groups from the O6 position of 
guanine [24]. The methylation status of the promoter region of the MGMT 
gene is one of the main mechanisms contributing to TMZ sensitivity 
(prolonged the survival to 2 years) or resistance in patients with GBM [25].  
Genetically, GBM is a highly heterogeneous tumor harboring multiple 
recurrent and non-recurrent genetic alterations. Within the same tumor, 
cytogenetically related and unrelated clones coexist. These findings have 
inspired the investigation of molecularly targeted therapies designed to 
target tumor-specific recurrent genetic alterations as a novel approach to 
treating GBM. Particular interest has focused on inhibitors that target 
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receptor tyrosine kinases such as epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor (PDGFR), and vascular 
endothelial growth factor receptor (VEGFR). Amplification of EGFR is one 
of the most common genetic alterations seen in GBM. Overexpression is 
the result of a mutant form of the receptor, EGFRvIII, which has a 
constitutively active kinase domain [26].   
Gefinitib and Erlotinib are oral small molecule EGFR TKIs, which binding to 
intracellular kinase domain of EGFR, inhibit the activation of its downstream 
signaling pathways [27,28]. 
Overexpression of PDGFR signaling is another frequent alteration found in 
GBM. Imatinib is a small molecule multikinase inhibitor that binds PDGFR 
as well as several other RTKs. Imatinib blocks the PDGFR kinase domain 
to prevent activation of its downstream signaling pathways. Unfortunately, 
similar to EGFR inhibitors, clinical trials with Imatinib demonstrated a lack 
of therapeutic efficacy and minimal clinical benefit [29]. 
Malignant glioma are among the most vascular of human tumors 
characterized by extensive angiogenesis. Vascular endothelial growth 
factor (VEGF), a critical mediator of angiogenesis, is highly overexpressed 
in GBM. Bevacizumab is a humanized monoclonal antibody that binds and 
neutralizes the VEGF ligand, preventing activation of its receptors [30,31]. 
Bevacizumab is thought to improve outcomes by reducing angiogenesis, 
decreasing growth of tumor cells expressing VEGF, disrupting the 
microvasculature of the tumor leading to increased tumor hypoxia, and 
increasing tumor cell sensitivity to RT. In clinical trials of recurrent GBM, 
bevacizumab demonstrated clinical benefit and improved progression-free 
survival [32]. 
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1.2 Glioblastoma 
Glioblastoma (WHO grade IV), is the most common and lethal glial tumors, 
accounts for 75% of all adult glioma diagnoses (Figure 3). Incidence of 
glioblastoma increases with age, with rates highest in the 75 to 84 years, 
and it is 1.6 times more common in males [4]. 
Glioblastoma and other malignant gliomas are highly invasive, infiltrating 
surrounding brain parenchyma, yet they are typically confined to the central 
nervous system (CNS) and do not metastasize [33]. 
It is characterized histologically by considerable cellularity and mitotic 
activity, vascular proliferation, and necrosis with cells arranged around the 
edge of the necrotic tissue (pseudopalisading cells) (Figure 4) [34,35]. 
 
 
Figure 3. Distribution of diffuse astrocytic and oligodendroglial tumours 
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Figure 4. Hematoxylin and eosin of glioblastoma (# pseudopalisading cell;   
                * vascular proliferation) 
 
 
On the basis of their genetic features GBMs are divided into IDH-wildtype 
or IDH-mutant. IDH-wildtype corresponds most frequently with clinically 
defined primary glioblastoma which is characterized by short presenting 
history and it arises de-novo with no detectable pre-existing lower grade 
tumor. It is predominant in elderly patients (mean age = 55 years). IDH-
mutant corresponds closely to so called secondary GBM with prolonged 
history and is typically preceded by a lower grade diffuse glioma. 
Preferentially arise in younger patients (mean age = 40 years) The majority 
of GBMs (~90%) are IDH-wildtype (Table 3) [2,36]. 
Whether a tumor is primary or secondary GBM cannot be predicted on 
basis of morphologic features. However the presence of large vessel 
thrombosis with large areas of infarction-like necrosis seems to be more 
prevalent in primary GBM. Prognosis and increased overall survival time 
seems to be better for the secondary tumors [37,38]. 
* 
# 
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Table 3. Differences and characteristics between IDH-wildtype and          
               IDH-mutant glioblastomas 
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Primary and secondary GBMs evolve from different genetic precursors and 
harbor distinct genetic alterations. Genetic alterations more typical for 
primary GBM are epidermal growth factor receptor (EGFR) overexpression, 
phosphatase and tensin homolog (PTEN) mutations, and loss of 
chromosome 10. Whereas genetic alterations more commonly seen in 
secondary GBM include isocitrate dehydrogenase-1 (IDH1) mutations, 
TP53 mutations, and 19q loss. Recent studies have also described 
mutations in the α-thalassemia/mental-retardation-syndrome-X-linked 
(ATRX) gene that are often copresent with IDH1/2 mutations and TP53 
mutations in diffuse astrocytomas and secondary glioblastomas (Figure 5) 
[39,40]. Although different gene expression patterns in primary and 
secondary GBM were identified, characterization of the IDH1 mutation has 
allowed for reliable molecular differentiation of primary from secondary 
GBM. Additionally, IDH1 mutations appear to be associated with better 
prognosis and increase in overall survival. Interestingly, IDH1 mutations are 
also found in greater than 80% of diffuse astrocytoma and anaplastic 
astrocytomas, which are precursors of secondary GBM and less than 5% of 
primary GBM. Thus, IDH1 mutations are a reliable, objective molecular 
marker for secondary GBM over clinical and pathological criteria [41–43].  
Using gene expression-based molecular classification of GBM that 
integrates multidimensional genomic data to establish patterns of aberrant 
gene expression and copy number alterations seen in GBM, four subtypes 
of GBM were identified. These GBM subtypes are classical, mesenchymal, 
proneural, and neural. Each subtype harbors distinct genetic alterations 
and expression profiles. The classical subtype is strongly enriched in the 
gene expression pattern observed in astrocytes. It is characterized by 
aberrant EGFR activity, leading to EGFR overexpression and loss of 
chromosome 10. Mutations in TP53, NF1, and IDH1 are uncommonly found 
in the classical subtype. The mesenchymal subtype is also enriched in the 
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gene expression pattern seen in astrocytes, but in addition, expresses 
mesenchymal markers as well as microglia markers.  It is characterized by 
alterations in the gene for NF1 and PTEN deletions. EGFR overexpression 
is less commonly seen in the mesenchymal subtype compared with other 
GBM subtypes. The proneural subtype is enriched in proneural genes as 
well as the gene expression patterns seen in oligodendrocytes. It is 
characterized by alterations in TP53, PDGFR, and IDH1. Neural subtype 
gene expression pattern is the most similar to that of normal brain tissue. It 
is strongly enriched in the gene expression pattern seen in neurons, and 
expresses both astrocytic and oligodendrocytic markers [44–46].  
 
 
 
Figure 5. Genetic pathways to primary and secondary glioblastomas 
 
 
15 
 
1.3 Neural Stem Cells  
Neural stem cells (NSCs) are multipotent cells within the brain capable of 
self-renewal and differentiation into all major cell types of the central 
nervous system (neurons, astrocytes and oligodendrocytes) [47]. 
The neural stem cell can be isolated from the walls of the ventricular 
system. The wall of the ventricular system is composed of a single layer of 
ependymal cells facing the lumen and a subventricular zone lying beneath 
the ependymal layer.   
Reynolds and Weiss [48] isolated cells from the adult mouse striatum, 
induced the proliferation of precursors within the cultures by administering 
epidermal growth factor, and found that the precursors differentiated into 
neurons and glia when the epidermal growth factor was withdrawn.                                                                                                                          
Richards and colleagues, [49] showed that precursors could be induced to 
differentiate into neuronal cells when they were initially stimulated in vitro 
with fibroblast growth factor-2 (FGF2) and then with medium conditioned by 
an astrocyte cell line. The multi-potential nature of these cells has been 
shown by clonal analysis, with such clones being able to give rise to both 
neurons and glia. The role of such cells, in rodents at least, might be to 
migrate to the olfactory bulb and differentiate into interneurons [50,51].  
The NSCs use several signalling pathways important for the proliferation. 
The Notch pathway is known to promote the survival and proliferation of 
neural stem cells and to inhibit their differentiation [52].  
In addition, the Notch pathway is also associated with tumor development, 
potentially as an oncogene [53]. Notch also promotes the expression of 
Nestin, a neural stem cell marker, in glioma cells [54]. 
Nestin is most highly expressed in ependymal cells and at lower levels in 
the rapidly proliferating subventricular zone progenitor cells in adult 
mammals. Interestingly, in response to spinal cord injury, Nestin expression 
is increased in ependymal cells, and with time, increasing numbers of 
Nestin-positive cells can be seen outside the ependymal layer, suggesting 
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that new cells may be generated from these cells in response to injury [55]. 
In the adult human hippocampus were demonstrated the presence of 
neurogenesis. The NSCs persist in the adult brain into senescence. The 
potential to generate new neurons may potentially be utilized to develop 
therapies in neurodegenerative diseases [56]. 
 
1.3.1 Glioma Stem Cells  
The tumors are composed of heterogeneous populations of cells. Malignant 
cells with functional properties, such as self-renewal, the capability to 
develop into multiple lineages, and the potential to proliferate extensively, 
that drive the formation and growth of tumours, have been called "cancer 
stem cells" [57,58].  
In the light of the repute only a few atypical cells within the cancerous mass 
might be responsible for the growth and recurrence of some tumours. Two 
hypothetical models have been proposed to explain this event. The 
stochastic model predicts that all cells in a tumor have a similar tumorigenic 
potential, which is activated asynchronously and at a low frequency in 
certain cells. Conversely, the hierarchical model that holds only in rare 
subset of cells within the tumor have significant proliferation capacity and, 
particularly, the ability to generate new tumours, with the remainder of the 
tumor cells or terminally differentiated cells representing differentiating. The 
latter hypothesis fits with the cancer stem cell theory (Figure 6) [59].  
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Figure 6. Stochastic and hierarchical model of tumor progression.  
                  A) Tumour cells are heterogeneous, but most cells can   
                  proliferate extensively and form new tumours; B) Tumour cells    
                  are heterogeneous and only the cancer stem cell subset (CSC,   
                 yellow) has the ability to proliferate extensively and form new            
                  tumours 
   
The first evidence for the existence of CSCs came from acute myeloid 
leukemia, in which a rare subset of cells comprising 0.01-1% of the total 
population could induce leukemia when transplanted into immunodeficient 
mice [60,61]. These concepts and experimental approaches were then 
applied to other  tumors such as breast [62], brain [63,64], colon [65], head 
and neck [66] and pancreas [67] cancers. 
In the brain tumors, the glioma stem cells (GSCs) as the neural stem cells 
(NSCs), can implement a long-term proliferation, differentiate into neurons, 
astrocytes and oligodendrocytes, but there are also some differences: the 
proliferation in vitro and in vivo of GSCs is greater than that of NSCs, their 
growth can to be independent of exogenous mitogens, so aberrantly 
express surface markers, chromosomal abnormalities, and possess, once 
implanted in vivo, are able to form tumors the histologically identical to 
which they were derived [68]. According to the hypothesis of GSCs, the 
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their definition and identification provide a multimodal approach that 
includes: 1. the analysis of the self-renewal capacity; 2. the analysis of the 
differentiation capacity in all cell lineages of the CNS; 3. the search for 
common markers with adult stem cells (for example, Nestin, CD133 etc.);  
4. verification of tumorigenicity when implanted into the brains of mice 
NOD-SCID [64,69]. 
The study of so-called "stem cell markers" led to the discovery of a subset 
of tumor cells that express a membrane protein called Prominina-1 
(CD133). The CD133+ cells are more resistant to radiation therapy, 
compared to CD133- counterparty both in vitro and in vivo and have 
increased expression of anti-apoptotic genes. It is a possible correlation 
between greater expression of CD133 and worst outcome of patients  has 
also been described [70,71].  
Although CD133, appears to be a robust marker of brain tumor stem cells 
in initial studies, more recent studies have found that this marker does not 
distinguish tumorigenic from non-tumorigenic cells, as there are GSCs 
CD133- populations also tumorigenic and capable of self-renewal [72,73].  
However, the most convincing demonstration of CSC identity comes from 
serial transplantation of a cellular population into the animal model, the 
universally recognized method for the functional evaluation of self-renewal 
and tumor propagation is precisely the ability to propagate the GSCs in a 
non-differentiated in vitro and to verify the tumorigenic capacity when 
injected into vivo [74]. 
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1.3.2 Glioma Stem Cells Niche 
The niche is a defined anatomical compartment that includes cellular and 
acellular components of residence, the stem cells - physiological and 
tumoral. The niche is constituted by a set of cells, blood vessels, 
glycoproteins and three-dimensional spaces which, together, form a highly 
specialized micro-environment in which the contact and communication 
between these components are critical for the maintenance of multipotency 
and the self-renewal of stem cells contained therein [75,76].  
Oxygen plays a fundamental role in maintaining the integrity of these 
microenvironments (Figure 7). It has been shown how the oxygen is able to 
regulate the fate in differentiative or apoptotic effect of various types of 
neural precursors, since it represents a source of free radicals and that 
oxidative stress induces apoptosis of oligodendrocytes and other cells of 
the central nervous system. Hypoxia is also able to influence the survival 
and cell proliferation by inhibiting apoptosis. These observations have been 
crucial for the study of GSCs. Although initially the GSCs had been 
described mainly in niches situated around the tumor vessels, recent 
evidence suggests the presence of niches away from vases, precisely 
defined hypoxic niches, adjacent to the necrotic edge of the lesion and 
where the GSCs are modulated in their activity, from genes induced by 
hypoxia, such as HIF (HIF-1 and HIF-2), Oct-4, VEGF, Notch, and c-Myc 
[77–79]. 
The hypoxic microenvironment present in the tumor mass is a result of 
rapid cell proliferation in which the newly formed vasculature are unable to 
compensate. In this model, the presence of perivascular GSCs could 
represent the result of the so-called "angiogenic switch" whose first 
triggering event would be precisely the presence of hypoxia [80,81].  
The cellular responses to hypoxia are regulated by a family of transcription 
factors Hypoxia Inducible Factors (HIFs). The HIFs factors are 
heterodimers consisting of an oxygen sensitive component, the α subunit 
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(HIFα), and by a component constitutively expressed, HIFβ. In normoxic 
conditions, HIFα is it is ubiquitinated by the product of the tumor suppressor 
gene von Hippel-Lindau (VHL) and directed to a proteasomal degradation; 
in hypoxia the interaction between HIFα and VHL protein is not leading to a 
stabilization of HIFα, which dimerizes with HIFβ and binds to hypoxia-
responsive elements (Hypoxia-Responsive Elements, HRE) among the 
promoters of the genes regulated by low levels of oxygen. The genes 
transcribed later the effect of HIF are hundreds and modulate the survival, 
motility, metabolism and angiogenesis. There are two forms of the protein 
HIFα, HIF1α and HIF2α, highly homologous sequences and that bind HRE 
similar [82]. Regions with poor vascularity are characterized by severe 
hypoxia, low pH and lack of nutrients; these areas of necrosis are frequent 
in rapidly proliferating solid tumors and hypoxia has been associated with 
resistance to treatments, local invasion and poor prognosis. Glioma stem 
cells might be protected further from conventional therapies by factors 
within the vasculature niche. Treatments that disrupt aberrant vascular 
stem cell niches could therefore prove active against gliomas, because they 
might also function to disrupt stem cell maintenance [76,83].  
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Figure 7. Role of oxygen in the maintenance of stemness in the Neural                                      
  (A) and Cancer stem Cell (B) 
 
 
Calabrese and colleagues demonstrated that stem cells from various brain 
tumors, including GBM, are maintained within vasculature niches that 
mimic the neural stem cell niche [81]. 
Notably, co-transplanting brain tumor stem cells and endothelial cells into 
immunocompromised mice, the initiation and growth of tumors in the brain 
were accelerated by the endothelial derived factors. Brain tumor stem cells 
seem to have potent angiogenic properties and can recruit vessels during 
tumorigenesis. It was shown that CD133-positive human GBM produced 
high level of VEGF and formed highly vascular and hemorrhagic tumors in 
the brains of immunocompromised mice. 
In vivo, GSCs reside in a micro-niche composed of microvasculature 
readily accessible to the serum, and attachments to the stromal and more 
differentiated cells, and their biological behaviors are thus highly dependent 
on their microenvironment. Proliferating cells are found in the hypoxic 
center. In fact, it was observed that GBM stem cells directly differentiate 
into endothelial cells lining tumor vessels [84,85]. As well as regulating 
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stem cell proliferation and cell-fate decisions, niches also have a protective 
role defending stem cells from environmental insults [86].  
 
1.4 Heat Shock Proteins 
Heat Shock Proteins (HSPs) are a highly conserved proteins family at 
cellular level, expressed in response to different types of stressors, capable 
of causing structural and functional alterations of cellular proteins. 
Among the physiological functions exerted by these chaperone there are: 
the movement of proteins within the cell compartments; folding of cytosolic 
proteins of the endoplasmic reticulum and mitochondrial; the contribution to 
the degradation of unstable proteins; the preservation by the formation of 
complexes and protein aggregates; and the action of re-folding of proteins 
partially denatured or incorrectly shaped [87–89]. 
The HSPs, in fact, have the task of ensuring the proper folding of proteins 
in their structure and facilitate transport within the cell compartments; they 
have also an important role in inducing thermo tolerance against strong 
thermal stress [90]. 
Heat Shock Proteins are so called because they produced following heat 
shock, but subsequently, were also observed as a consequence of 
pharmacological treatments or oxidative stress. 
The discovery of HSPs is often attributed to Ritossa which, in 1962, 
observed in the salivary cells of the fruit fly, Drosophila, as a result of 
thermal shock [91]. Following this discovery many researchers were 
interested to HSPs, highlighting the expression of these proteins in other 
organisms such as chicken embryos, yeasts and plants.  
It is believed that the expression of HSPs takes place in consequence of 
the binding of a transcription factor, HSF (Heat Shock Factor), for the HSP 
activated, with particular promoter regions called HSE (Heat Shock 
Element) located close to coding genes for the HSP [92,93].  
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Most of these genes do not contain introns, and the mRNA can be 
immediately translated into protein within a few minutes of exposure to the 
stressor. The stressor causes the transformation HSF from its inactive to 
active form shape, resulting in synthesis of HSP proteins. Although there 
are many hypotheses, about the mechanism through which the stress 
"active" the HSF, about the cell can “sense” the stress signal and translate 
that signal in response that lead to protein synthesis, it has not yet been 
clarified. 
 
1.4.1 Classification of HSPs 
Mammalian HSPs have been classified in two groups according to their 
size: high molecular weight HSPs and small molecular weight HSPs (Table 
4). The first group includes three mayor families: HSP90 (Hsp90α, Hsp90β, 
TRAP1), HSP70 (HSP70, Hsc70, HSP73, GRP78), and HSP60.  
Some of them are expressed constitutively; whereas, expression of others 
is induced only by stressful conditions and are confined to different cellular 
compartments such as cytosol, endoplasmic reticulum, mitochondria.  
These proteins are molecular chaperones ATP-dependent and require the 
presence of cofactors called co-chaperones, such as Hsp40, Hop, Hip, Hip, 
bag1, to regulate their conformation and ATP-binding [94].  
The HSP70 family constitutes the most conserved and best studied class of 
HSPs. It encompasses proteins ranging from 66 to 78 kDa (kiloDalton) 
localized mainly in cytoplasm (HSP70 or HSP72) or in mitochondria 
(mtHSP70) and one in the endoplasmic reticulum (GRP78/BiP). HSP70 
proteins assist the folding of newly synthesized polypeptides, the assembly 
of multi-protein complexes, transport of proteins across cellular membranes 
and lastly, act as molecular chaperones [95]. 
Prominent members of the HSP90 family of proteins, that encompasses 
proteins ranging from 85 to 90 kDa, are Hsp90α, Hsp90β. These two 
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HSP90 isoforms are essential for the viability of eukaryotic cells, and are 
associates with a number of signalling proteins including ligand-dependent 
transcription factors, such as steroid receptor [96,97].  
Mammalian HSP60, also called chaperonin, is mostly contained within the 
mitochondrial matrix although it can also be detected in cytosol. HSP60 is a 
constitutively expressed HSP, but its expression can increase after stress. 
HSP60 participates in the folding of mitochondrial proteins and facilitates 
the proteolytic degradation of misfolded or denatured proteins [98,99]. 
The second group includes small HSPs proteins that vary in size from 15 to 
30 kDa. 
HSP27, probably the most studied member of this family, is an ATP-
independent chaperone whose main function is protection against protein 
aggregation. It is expressed in many cell types and tissues, at specific 
stages of development and differentiation. In cancer cells, the basal 
expression of HSP27 is abnormally high and associates with cell resistance 
to anticancer therapy [100]. 
 
1.4.2 HSP90/TRAP1 
The main member of the Heat Shock Proteins family is HSP90, one of the 
most conserved molecular chaperones and present in many organisms 
from bacteria to humans. Participates to the regulation of many client 
proteins involved in signaling processes, cell proliferation and survival. The 
HSP90 family is distinguished compared to the other molecular chaperones 
because many of its substrates are known to be protein transduction 
signals, such as for example the receptors for steroid hormones and 
signals for the kinase [97,101].  
HSP90 is one of the main species of molecular chaperones that need ATP 
to carry out their functions. They are among the most abundant proteins 
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present in the cells in fact represent 1-2% of total cellular protein, the value 
of up to 4-6% in the cellular stress conditions [102].  
In particular, HSP90 appears to be very abundant in the cytosol, the 
endoplasmic reticulum, and in mitochondria, and their natural abundance 
can make difficult the identification of other classes of heat shock proteins 
whose synthesis can be induced exclusively by exposure to stress. The 
main task of HSP90 is to stabilize protein before occur their completed 
folding or their activation, but they also play a key role in the dense network 
of signal transduction, cell cycle control, in the degradation of proteins and 
in the movement protein [103]. 
The association of the HSP90 with many cellular proteins seems that 
induces or inhibits the normal function of these proteins, also they form 
stable complexes with transcription factors. To fulfill their role within the 
cells, HSP90 act as part of a multi chaperon machine in association with 
HSP70 and cooperate with a number of co-chaperones. 
HSP90 is ubiquitously expressed in all normal cells and is over-expressed 
in tumor cells. HSP90 has a critical role for tumor cells, since it allows to 
maintain the functions of mutant proteins built up during the process of 
carcinogenesis and also seems to be actively involved in the protection of 
cells from apoptosis; so the over-expression of HSP90 corresponds in 
many types of cancers, a negative prognosis in terms of survival and 
response to therapy. The molecular mechanisms that involve this 
chaperone in resistance to anticancer therapies concern, in reality, different 
aspects: HSP90 efficiently ensures cytoprotection repairing the damage 
caused by the administration of cytotoxic drugs; protects cancer cells from 
apoptosis spontaneous, preserves the internal micro-circulation to the 
tumor and even improves the repair of DNA damage. In light of this, HSP90 
emerges as a promising target in cancer treatment [104]. 
26 
 
HSP90 exists in the form of a homodimer composed of four parts: N-
terminal part contains the binding site for ATP; a linker between the N-
terminal region and the intermediate region; intermediate domain; C-
terminal domain where there is a second binding site for ATP.  
They have been identified five isoforms of HSP90 which differ in the cellular 
localization. The two HSP90α and HSP90β, GRP94 that is in the ER, 
TRAP1 in the mitochondrial matrix [96]. 
TRAP1 was initially identified as a homologue of HSP90, since it has a high 
homology in the most conserved region, the N-terminal. The first function 
attributed to TRAP1 was the protection of mitochondria against oxidative 
stress induced by ROS (Reactive Oxygen Species). It can interact with the 
TNF receptor and the retinoblastoma protein (Rb). Hsp90 and TRAP1 are 
abundantly present in the mitochondrial compartment of cancer cells, while 
found at low levels in normal cells. TRAP1 represents a protection factor of 
cell apoptosis, inhibits with HSP90 the intrinsic pathway by blocking the 
apoptotic process in the early stages [105,106].  
The use of inhibitory drugs, such as Geldanamycin (GA) and the Radicicolo 
(inhibitors of the ATPase pocket) leads to a block in the malignant cell 
proliferation. These molecules in fact, prevent HSP90 to fold and stabilize 
the client proteins, which are associated in a non-functional complex and 
therefore are degraded by the proteasome dependent ubiquitination and 
proteolysis [107,108]. 
The drugs used conventionally as HSP90 inhibitors can be effective also in 
inhibiting the function as the at the mitochondrial level. The first molecules 
synthesized to act on mitochondrial targets have been defined as 
Gamitrinibs (GA mitochondrial matrix inhibitors). These inhibit the ATPase 
activity of TRAP1 directly inducing the increase of mitochondrial 
permeability thus leading to the loss of membrane potential and the release 
of cytochrome c into the cytosol. The GAM derived from a combination of 
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three parts: the GA (Geldanamycin), or rather its derivative, 17-AAG; a 
repeated structure of guanidinium salts; a linker that links the two portions. 
The accumulation in the mitochondria due to a rapid loss of potential of the 
inner membrane and, only in the cytosol of the tumor cell, restores the 
release of cytochrome c. The GAM shows, in fact, a modest or no 
cytotoxicity on normal cells at doses sufficient to cause the death of cancer 
cells [109]. 
 
 
 
 
Table 4. Classification of mean heat shock proteins and subcellular   
               localization 
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1.4.3 HSP70 
It is the most conserved family, presents a high levels of sequence 
conservation in all species where it has been identified [110,111].  
HSP70 are constituted by two major functional domains, the first portion is 
present in the N-terminal of the protein of about 40 kDa with ATPase 
function, and the second is present in the C-terminal portion of the protein 
of about 25 kDa peptide-binding. The two domains are separated by a 
region susceptible to the cut of the protease. Since the HSP70 are localized 
in the cytosol, the endoplasmic reticulum (ER), in the mitochondria, in the 
precursors of the members intended to be transported within these 
organelles, it is present, at the N-terminus, a transit peptide with a 
sequence variable. For many HSP70, the presence of a sub-domain to the 
C-terminus of about 5 kDa, it is essential to allow interaction with their co-
chaperones. The wide spectrum of functions of HSP70 is due to the 
intervention of co-chaperon that perform specific cellular functions in 
cooperation with the HSP70 [112].  
They are activated as a result of stress. The induction heat of Hsp70 is 
mediated by heat shock transcription factor (HSF) that correspond to the 
heat shock elements (HSE) in the promoters. The active trimeric HSF bind 
the HSE present in the promoters of many genes inducible by heat, 
including the HSP70. In conditions where there is no thermal shock, either 
HSP70 binds to inactive HSF or remains as free HSP70. During the heat 
shock, the pool of free HSP70 is reduced by binding denatured proteins by 
heat, that releases the HSF from HSP70. The presence trimeric HSF 
activated in the nucleus promotes transcription of HSP70 thereby 
increasing the amount. The HSP70 excess capture the HSF newly 
synthesized before they are brought to the nucleus and form a trimeric 
structure, so that from time to time attenuates the expression of HSP70-
induced heat and others HSPs. The cytosolic HSP70 are involved in 
cellular processes such as protein folding, refolding of the denatured 
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proteins, prevention of protein aggregation and maintain the protein in a 
state of competent amount in eukaryotes [113,114].  
It was therefore suggested that the cytoplasmic HSP70 are involved in the 
translocation of the ER protein precursors. The lumen of the ER, where the 
pathways of secretion of the precursor proteins are generally co-
translocated, belongs a member of the HSP70 family, GRP78/BiP. It is 
considered one of several chaperones to be involved in the translocation of 
precursor proteins across the ER membrane, the protein folding, assembly 
and binding to proteins with incorrect folding into the lumen of the ER. The 
GRP78/BiP expression is induced by stress conditions which lead to 
proteins having an incorrect folding. Many studies have shown that 
overexpression of BiP relieves stress to the ER by restoring the processing 
of secreted proteins and the folding [115–117]. 
 
1.4.4  ER Stress 
In eukaryotic cells the endoplasmic reticulum (ER) is the first compartment 
in the secretory pathway. Inside this organelle proteins are synthesized, 
correctly folded to get the right shape and modified to make them finally 
functional. The properly folded and modified proteins are then translocated 
to the Golgi complex, and are retained in the reticulum the not folded 
properly or proteins that must be degraded. The alteration of any of these 
processes cause ER stress. The ability of the cell to respond and solve 
these alterations is essential to maintain its normal homeostasis [118,119]. 
When the cell are exposed to any stress, one of the main consequences is 
the accumulation in the lumen reticulum of protein not folded correctly. To 
maintain their homeostasis, cells active two different answers; first is the 
"Unfolded Protein Response" (UPR), which leads to activation of 
transcriptional genes coding for molecules resident in the endoplasmic 
reticulum and facilitate proper protein folding. These molecules, called 
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"chaperones", such as GRP78/BiP and GRP94, promote the right setting 
protein folding trying to limit the increase of unfolded proteins. 
The second answer is instead, a radical and rapid suppression of protein 
synthesis to prevent other proteins are synthesized. The repression of 
protein synthesis occurs in the stress response in mammalian cells through 
the increase of eIF2α phosphorylation. eIF2α phosphorylated interferes 
with the formation of translation initiation complex by blocking the 
translation itself. In ER stress eIF2α is phosphorylated by PKR and 
PEK/PERK, repressing the synthesis. Phosphorylation of eIF2α is the only 
way known that regulates the suppression of protein synthesis in response 
to the reticulum stress [120].  
The UPR, on the other hand, begins as soon as the balance within the 
endoplasmic reticulum is compromised. Three different transmembrane 
proteins resident in the reticulum have been identified as "sensors" of the 
presence of ER stress: IRE1 (α and β), a kinase and endoribonuclease, the 
kinase PERK and the transcription factor ATF6 (α and β) (Figure 8). 
IRE1 and PERK, activated after stress, homodimerizes, 
autophosphorylates and then are activated, while ATF6 translocates to the 
Golgi. Into the Golgi it is cut by the two proteases, S1P and S2P, 
generating a transcription factor activated.  
The combined effect of the activation of all three of these molecules 
involves a positive regulation of genes encoding chaperones and for 
proteins involved in the degradation and a negative regulation of protein 
synthesis and the consequent inflow of nascent proteins within the 
reticulum. 
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Figure 8. Upon accumulation of unfolded protein in the ER lumen, IRE1, 
                         ATF6, PERK are active UPR and/or suppression of synthesis 
 
 
1.4.4.1 GRP78/BiP and Endoplasmic Reticulum Stress 
The activation of all three UPR components depends on dissociation from 
these of a fourth molecule, enormously abundant in the lumen of the 
reticulum, GRP78/BiP.  
BiP is an ATPase, member of the "heat shock protein 70 family". In 
unstressed cells IRE1, ATF6 and PERK are retained in the lumen of the 
reticulum by BiP, which is associated to their luminal domain. BiP on the 
other hand, is also the main chaperone of the cell, is associated so even 
with the newly synthesized proteins to allow the correct folding [121].  
In a cell not stressed, BiP is in continuous balance between binding to 
proteins to fold and binding to the stress sensors. If, however, any stress 
leads to increased protein not folded properly, the balance shifts; most of 
BiP is bound to proteins which have to be folded and the sensors, IRE1, 
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ATF6 and PERK are free and can be activated. As previously described 
IRE1 and PERK are free to form dimers and phosphorylate themselves, 
while ATF6 is free to transit the Golgi complex, and there be cut from its 
two proteases. Though IRE1, PERK and ATF6 are all activated 
simultaneously by the dissociation of BiP, each of the pathways activated 
by these is temporally distinct. This allows that different parts of the same 
UPR are adjusted each from different molecules [119].  
After exposure to stress the way as quickly activated is the repression of 
protein synthesis mediated by PERK. Given that eIF2α is directed substrate 
of kinase, phosphorylation occurs immediately and blocks very quickly 
cellular translation [122].  
Also the proteolytic cleavage of ATF6, and then its activation occur quickly 
after the stress occurred, but the expression of genes under its control, 
however, requires the nuclear translocation of its cytoplasmic domain 
activated, the induction of the transcription and synthesis, then longer 
times. Since the activation of ATF6 leads to the induction of many genes for 
chaperones, such as for example the same BiP and GRP94, this increases 
the ability of the protein folding pattern, and then the restoration of 
homeostasis. Following the synthesis block operated by eIF2α this can be 
seen in a certain way as the second stage of the UPR response [123]. 
During UPR, the transcription it is also positively regulated by ATF4, a 
transcription factor member of cAMP Response-Element-Binding (CREB) 
family. ATF4 requires for his translation the eIF2α phosphorylation. This 
transcriptional factor in fact, contains ORF at its 5' non-translated which in 
normal conditions not allow the translation, but in the presence of 
phosphorylated eIF2α allow the production of ATF4. The activation of IRE1 
leads to transcriptional induction, but the activation of this pathway occurs 
after the activation of ATF4 and ATF6 [124,125].  
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2. AIM OF THE STUDY 
The aim of this study was to assess whether the HSP90-GRP78 axe 
expression in peri-necrotic tumor areas or pseudo-palisading cells 
contributes in maintaining a pro-survival environment and whether it is 
regulated by hypoxic stimuli. Identify a subset of human gliomas in which 
the cancer-stem cell niche is sustained by high GRP78 expression and a 
hypoxic environment and determine whether GRP78 also promotes tumor 
cell migration, thus further plays roles in glioma cancer stem cell 
maintenance and in glioma cell motility and contributing in brain tumor 
relapse. At last, to define the contribution of molecular chaperones in 
glioma modulation of HSP-GRP78 axe by specific drugs in ex vivo glioma 
tissue cultures, to provide targets for novel therapies useful to improve 
prognosis of patients affected by brain tumors. 
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3. MATERIALS AND METHODS 
3.1 Human samples 
An Ethical Committee approved the study and informed consent was 
signed by all enrolled patients. A series of patients’ recruited at IRCCS Ca’ 
Granda between 2013-2016, with correlation of molecular profiles to clinico-
pathological characteristic were enrolled (Table 5). We collected 123 fresh 
human samples of brain cancers (89 grade IV, 16 grade III, 16 grade II, 2 
grade I).  
 
3.2 RNA purification and qRT-PCR 
Samples were homogenized in 1 ml of Tizol® reagent (Ambion Thermo 
Fisher Scientific) using a tissue lyser (Qiagen). Tissue lysates were 
incubated for 5 min at room temperature. 200 μl of chloroform were added. 
Samples were centrifuged for 15 min at 13000 rpm and 4 °C and the upper 
aqueous phases were recovered. 500 μl of 100% isospropanol were added 
and samples were incubated at -20 °C over night. Samples were 
centrifuged for 15 min at 13000 rpm and 4 °C. Pellets were washed with 
75% cold ethanol and dissolved in H2O. The total RNA was quantified by 
spectrophotometer Nanodrop1000 (Thermo Fisher Scientific). 
We performed retro-transcription with 300 ng (gliomas samples) of RNA 
using High Capacity cDNA Reverse Trascription Archive Kit (Thermo Fisher 
Scientific), according to the manufacturer’s. 
For gene expression quantification Human TaqMan Assays (Applied 
Biosystems) and reagents were used following the manufacturer’s 
specification. Relative gene expression levels were normalized to ribosomal 
RNA 18s levels (housekeeping gene) and presented as Log 2−ΔCt. The 
instrument ABI PRISM® 7900HT (Applied Biosystems) was used for the 
analysis. 
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3.3 Tissue Micro Array (TMAs) 
Tissue micro-arrays (TMAs) with representative cores of tumor (four per 
case) or normal (one per case) parenchyma was generated from 187 
patients affected by brain cancers and by 100 corresponding normal brain 
counterparts (Table 6). Tissue cores were arranged in seven TMA blocks. 
Tumor histotypes included astrocytomas WHO Grade II or III (anaplastic), 
oligodendroglomas WHO Grade II or III (anaplastic), and glioblastomas 
WHO Grade IV. Hematoxylin and eosin (H&E) staining was used to control 
suitability of TMAs prior to immunohistochemistry. 
  
3.4 Immunohistochemistry (IHC) 
For each TMA block, 4 μm-thick sections were stained with GRP78 
(1:1000, C50B12, CellSignaling), TRAP1 (1:200 HPA044227, Sigma 
Aldrich), Bcl2 (prediluited, 124, RocheVentana), and HIF-1α (1:200, 
54/HIF1α, BDBioScience) using citrate buffer in antigen retrieval step. 
Immunohistochemistry was performed using Benchmark Ultra Roche 
Ventana immunostainer. Endogenous peroxidase activity was blocked by 
hydrogen peroxide (0,3%) for 10 minutes. The chromogen 
diaminobenzidine (DAB) was incubated for 8 min at room temperature. All 
slides were counterstained with haematoxylin. 
A pathologist blinded to clinical data evaluated immunohistochemical 
results. 
 
3.5 Cell lines  
Human Glioma LN229 (Glioblastoma), SW1088 (Astrocytoma) and T98G 
(Glioblastoma) cells were purchased from the American Type Culture 
Collection (ATCC). Glioma cell lines were cultured in RPMI (Gibco-Thermo 
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Gibco-
Thermo Fisher Scientific) and 1% of Penicillin and Streptomycin (Pen-
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Strep, Gibco-Thermo Fisher Scientific) and were maintained in 5% CO2 
humidified incubator at 37°C, as recommended by the manufacturer. 
Human glioblastoma U251-HRE cell were a generous gift from Dr. Ottobrini 
(University of Milan - Centro di Imaging Molecolare e Cellulare IMAGO). 
Cells were cultured in RPMI supplemented with 10% FBS and 1% 
Pen/Strep and maintained in a humidified atmosphere of 5% of CO2 at 
37°C. U251 cell line expressing the Luciferase a reporter gene under the 
control of a hypoxia responsive element (HRE) a inducible promoter, were 
used to assess the modulation of HIF-1α activity as consequences of a 
reduced O2. In this way, the activity of HIF-1α can be visualized by non-
invasive techniques, using luciferase activity as a hypoxia biosensor. 
 
3.6 Cell lines transfection 
LN229, SW1088, T98G, and U251 cells were seeded at 1x105 cells/well in 
6-wells plates and cultured in 2 ml of complete media for 24 h. Cells were, 
then transfected with 100 pM of MissionEsiRNA GRP78 and siRNA TRAP1 
(Sigma-Aldrich) or negative controls (Sigma-Aldrich). Were utilized 5 μl 
Lipofectamine 3000 (Thermo Fisher Scientific) as transfection reagent in a 
final volume of 500 μl of OptiMem medium (Gibco-Thermo Fisher 
Scientific). After 5 h the transfection medium was replaced with 2 ml of 
RPMI (Gibco-Thermo Fisher Scientific) complete medium and cells were 
maintained in a 5% CO2 humidified incubator at 37°C for 48 h and 
processed for individual experiments. 
 
3.7 Apoptosis and cell cycle analysis 
After 48 h from transfection, LN229, T98G or SW1088 cells were 
trypsinized and cells suspension was centrifuged at 1000 rpm for 5 min. 
Each pellet was washed with HBSS (Gibco-Thermo Fisher Scientific) and 
re-suspended in 600 μl of 1% FBS in PBS (Gibco-Thermo Fisher Scientific). 
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Then, 1.4 ml of cold absolute ethanol were added drop to drop and cells 
were incubated at -20°C over night. Fixed cells were centrifuged at 1000 
rpm for 3 min, the pellet was washed with PBS and re-centrifuged at 1000 
rpm for 3 min. The pellet was re-suspended in 500 μl of propidium iodide 
(PI)RNAase Stainig Buffer (BD Pharrmigen), to analyze cell cycle transition 
by FACS Canto I Flow Cytometer (BD Biosciences).  
Alternatively, apoptosis cells were stained with Annexin V/PI using the FITC 
Annexin V Apoptosis Detection Kit (BD Bioscience, San Diego, CA, USA), 
according to the manufacturer’s. 
Evaluated by multiparametric flow cytometry and analyzed using FlowJo 
software. 
 
3.8 Side population analysis 
Transfected LN229 cells were resuspended at 1x106 cells/ml in pre-warmed 
DMEM supplemented with 2% FBS and 10mM HEPES (Thermo Fisher 
Scientific). Hoechst 33342 (Cell Signaling Technology Inc) dye was added 
at final concentration of 5 μg/ml in presence or absence of 50 μM 
Verapamil (Sigma-Aldrich) and cells were incubated at 37°C for 2 h with 
intermittent shaking. At the end of the incubation, cells were washed by 
centrifugation at 4°C with ice-cold HBSS (Gibco-Thermo Fisher Scientific) 
and resuspended at the final concentration of 2x107 cells/ml with cold HBSS 
supplemented with 2% FBS and 10 mM HEPES. In order to exclude dead 
cells, propidium iodide (Sigma-Aldrich) was added at the final concentration 
of 5 μg/ml. SP analysis and cell sorting were conducted on FACS Aria III 
(Bencton Dickinson, San Josè, CA, USA) equipped with a FACS Diva 
software (version 7.0).  
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3.9 Cell invasion analysis 
After 48 h from transfection, the pellet of cells were counted using trypan 
blue (Cambrex Bio Sciences) and diluted at the concentrations of 1.25x105 
cells/ml using a medium devoid of FBS. Rehydrated Matrigel insert (BD 
BioCoat Matrigel Invasion Chambers BD Biosciences) were placed  in a 24-
wells plate and immersed in a chemotactic medium containing 10% FBS. 
Then, 500 μl (2.5x104 cells) of cells suspension were seeded into Matrigel-
inserts and incubated in a 5% CO2 humidified incubator at 37°C for 24 h. 
Cells on the lower surface of the membrane can be fixed, stained with 
Toluidine Blue and counted at the microscope. 
 
3.10 Cell migration analysis 
After 48 h from transfection, a wound was created in the monolayer of 
LN229 and SW1088 cells using a P200 micropipette tip. Then the cells 
were washed in PBS and incubated in complete medium for additional 24 h 
before analysis. For the analysis, random pictures were taken at 5x 
magnification when the scratch was performed (T0) and after 24 h (T24). 
The migration (units) was determined as reduction in the wound’s gap 
using NIH Image-J software. 
 
3.11 Immunoblotting 
Aliquots of U251 cells were harvested, 48 h post-transfection, and 
solubilized in 100 μl of RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% TritonX) supplemented with 1X 
complete protease inhibitor cocktail (Roche). Cell lysates (50 μg) were 
separated by electrophoresis on 8% SDS-polyacrilamide gels, transferred 
to PVDF membranes (Millipore), probed with primary antibodies against 
GRP78 (Cell Signaling), TRAP1 (Sigma-Aldrich), HIF1α (BD Biosciences), 
or β-Tubulin (Sigma-Aldrich). Primary antibodies were probed with anti-
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mouse or rabbit secondary antibodies (Bio-Rad) and reactive bands were 
visualized in chemiluminescence with ECL Plus reagents (GE Health Care). 
 
3.12 Hypoxia by Petaka system  
Post-transfection, aliquots of U251 cells were harvested (6x105 cells). The 
pellet  was added  with 15 ml of RPMI supplemented with 10% FBS and 
1% Pen/Strep. Through a 18-gauge needle, the cells were injected into 
PetakaG3™ Low Oxygen Transfer (Celartia) and maintained in a 
humidified atmosphere of 5% of CO2 at 37°C, for 24 h and processed for 
individual experiments. 
 
3.13 Luciferase reporter assay 
U251 cells, 48 h post-transfection, were rinsed with 1X PBS. Then, 
removed all rinse solution were dispensed 500 μl of 1X PLB for 15 min at 
room temperature, to perform lysis. Into a  luminometer tube pre-dispensed 
100 μl of LAR II (Dual-Luciferase Reporter assay, Promega) and were 
added 20 μl of PLB lysate. Briefly, lysates were analyzed by a luminometer 
GloMax20/20 - Detection System, Promega) data were normalized to the 
amount of proteins (Bradford assay) and expressed as relative 
luminescence/fluorescence units (RLU/FLU = counts/mg proteins). 
 
3.14 Organotypic tissue culture 
Organotypic tissue slices were generated through vibratome (VT1200 Leica 
Microsystems) serial cutting of fresh tumors (300 µm), and slices were 
cultured on dedicated supports from Millipore. Ex vivo organotypic glioma 
tissue or glioma cell lines were cultured up to 72 hours in presence or 
absence of 100 µM or 200 µM Temozolomide, Gamitrinibs (to inhibit HSP 
signaling). As control sample we used an untreated tissue slice cultivated in 
complete media supplemented with vehicle (1 µl of DMSO in 1 ml of 
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media). Tissue cultures were formalin-fixed and paraffin-embedded (FFPE) 
for molecular or morphological (hematoxylin and eosin staining) and 
immunohistochemistry analyses. For each glioma culture tissue 
proliferation (Ki67 labeling), apoptosis (cleaved Caspase-3), and PI3 
Kinase/AKT signaling, protein presence and expression in cultivated tissue 
slices were evaluated by immunohistochemistry (IHC) and scored as 
percentage of positive cells out of the total. IHC scores in cultivated tissue 
slices are expressed relative to baseline uncultured sample (T0).  
 
3.15 Statistical analyses 
Groups’ comparisons were performed by Student t Test with Welch 
correction if appropriate. Survival curves were made according to Kaplan-
Meier method and analysis were performed using log Rank test. 
P values ≤0.05 were considered statistically significant. 
For human samples (n=123 patients), data were analyzed using a 
GraphPad Prism©5 (GraphPad Software Inc., San Diego, CA, USA) 
software package for Windows. 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
 
 
 
 
 
 
 
Table 5. Characteristics clinico-pathological of 123  patients’ enrolled in the   
                study (* average) 
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Table 6. Characteristics clinico-pathological of 187 patients’ arranged in  
               tissue microarray 
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4. RESULTS 
4.1 GRP78 is up-regulated in human gliomas   
The presence of GRP78 was confirmed at gene expression level in a 
patient’s clinical series of fresh samples composed by 82 GBM IDH1 wild 
type, 7 GBM IDH1-mutated, 16 grade III and 18 low grade and correlated to 
their clinical features and/or prognosis. The GPR78 expression was 
significantly enriched in high grade gliomas respect to lower grades (**, 
P<0.001; Figure 9). 
Therefore, were analyzed GRP78 and TRAP1 expression in a second 
larger set of gliomas arranged in tissue microarrays (TMAs) derived from 
187 patients and in 85 normal brain counterparts. 
Immunohistochemical analysis showed that GRP78 (***, P<0.001; Figure 
10), and TRAP1 (*, P<0.01; Figure 11) are overexpressed by brain tumors 
compared to normal counterparts independent of tumor grade, and by high-
grade gliomas compared to lower grade tumors. Investigating expression 
pro-survival and hypoxia markers, such as Bcl2 and HIF-1α respectively, 
we could detect an association between high GRP78 expression in peri-
necrotic tumor areas (asterisk in Figure 12) and increased expression of 
Bcl2 and HIF-1α. 
Furthermore,  in regards to prognosis, higher protein levels of GRP78 were 
correlated to poor prognosis in the series of glioma patients as showed by 
survival curves (P<0.0001; Figure 13). 
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Figure 9. Real Time q-PCR analysis of GRP78 expression in human 
                            glioma with different grade (**, P<0.001) 
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Figure 10. A) Quantification of GRP78 in human gliomas with different grades                     
                  and in normal brain parenchyma. B) Representative picture of human                    
                  gbm obtained by GRP78 staining (20x magnification) 
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Figure 11. A) Quantification of TRAP1 in human glioblastomas and in normal                    
                  brain parenchyma. B) Representative picture of human gbm obtained                  
                  by TRAP1 staining (20x magnification) 
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Figure 12. GRP78 is enriched in glioma areas characterized by elevated HIF1α                               
                  and Bcl2 expression (*necrotic area) 
 
 
Figure 13. Glioma patients’ overall survival according to GRP78 expression 
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4.2 GRP78 inhibition decrease viability and motility of GBM cell lines 
Functional experiments were performed on a panel of glioma cells lines 
such as LN229 (GBM), T98G (GBM), SW1088 (Astrocytoma) and U251-
HRE (GBM) to understand whether knock-down of HSPs influenced the 
vitality of tumor cells. The transient silencing of cell lines were modulated 
for GRP78 and TRAP1 expression by siRNA or esiRNA. 
Effectively, a decreased of mRNA levels (***, P<0.001; Figure 14) and of 
proteins (Figure 15) in knock-down of GRP78 and TRAP1, respect to 
control were been demonstrated. 
Moreover, to assess whether the GRP78 inhibition induce cell death we set 
up the Annexin-V assay. It was highlighted an increase in apoptotic cell 
death in GRP78-silenced cells respect to control transfected ones (Figure 
16). 
Depletion of GRP78 affected also cell motility, in fact cell invasion was 
decreased with a reduction of invaded cells of about 70% in LN229, and 
cell migration was decreased also in cell line low grade such as SW1088 
respect to control (Figure 17A, 17B). 
Globally, GRP78 silencing decreased cell migration and partially affected 
cell viability. 
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Figure 14. Real Time q-PCR analysis of GRP78 and TRAP1 expression in   
                    glioma cell line, LN229, T98G, SW1088, and U251 after gene     
                    silencing of GRP78 and TRAP1 (***, P<0.001) 
 
 
 
 
 
 
 
Figure 15. Immunoblot for GRP78, TRAP1 and βTUBULIN expression in U251   
                  modulated cells 
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Figure 16. Annexin V assay. Increases of apoptosis in glioma cell lines (LN229   
                  and SW1088) after siRNA silencing compared to control 
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Figure 17. Motility in glioma cell lines. Decrease the ability of invasion (A) 
 and migration (B) in glioma cell line, LN229 and SW1088, after  
                    gene silencing of GRP78. (**/***, P<0.005) 
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4.3 GRP78 is present in stem cell niche of GBM 
Flow cytometry analysis for ABCG2 function usually identifies the side 
population as a very small fraction of cells in tumors. Consistent with this, 
we found a small percentage of tumor cells expressing ABCG2. 
The presence of the side (SP) or the non-side (NSP) populations of glioma 
cell lines such as LN229 (GBM), T98G (GBM) were isolated through FACS-
sorting procedures after GRP78 knockout through siRNA or control 
transfected cells: percentage of SP decreased  in modulated cells respect 
to control (***, P<0.001; Figure 18). To characterize the cells that actively 
contribute to the SP phenotype, we performed a Hoechst dye exclusion 
assay on GBM cell lines. As most cells accumulate Hoechst 33342, SP 
cells can be isolated by dual-wavelenght flow cytometry based on their 
ability to efflux this dye, a process that requires the action of the ABC 
transporters. We identified a side population among cells isolated from 
tumor samples. This SP fraction was generally small, ranging from 0.5% to 
1% of total cells. 
Tumor samples exhibited some regions of cells positive for some typical 
stem cell marker. The expression of stem cell markers (ABCG2, NANOG), 
the hypoxia transcription factor (HIF1α), and the expression of GRP78 were 
analyzed by qRT-PCR in SP or NSP cells populations (Figure 19). Globally, 
gene expression levels of all analyzed markers were higher in the side-
population (SP) respect to non-side population (NSP). This data is in line 
with the expectation of  the presence of stem niche in glioma cancer.  
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Flow cytometry analysis in glioma cell line (LN229), silenced for   
                  GRP78 to identified SP and NSP (***, P<0.001) 
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Figure 19. Real Time q-PCR analysis of ABCG2, NANOG, HIF1α and                    
                  GRP78 expression in glioma cell line (LN229, T98G), SP and NSP. An   
                  increase of all marker in SP respect to NSP is shown 
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4.4 HSPs and hypoxia 
To assess the role of HSP90-GRP78-HIF1α axe expression in hypoxia we 
used in vitro characterization of Luciferase Activity after HIF-1α modulation. 
To modulated hypoxia we used PetakaG3™LOT (Low Oxygen 
Concentration) system, which is an innovative bioreactor able to decrease 
oxygen concentration within the limits of the oxygen tensions in physiologic 
tissues (from 75 mmHg down to 15 mmHg). U251-HRE cells expressed the 
luciferase reporter gene in relation to HIF-1α nuclear accumulation. 
Luciferase activity was seen to increase after esiGRP78 in U251-HRE cells 
in hypoxic conditions, respect to control (Figure 20A). Conversely, 
luciferase activity decreased in U251-HRE cells TRAP1-silenced after 
induction of hypoxia by LOT system, compared to control (Figure 20B). 
These data were confirmed by protein levels (Figure 21A, 21B), in fact the 
protein HIF1α results augmented in hypoxia conditions after GRP78 
silencing in U251-HRE cells, while, the levels of Hypoxia Inducible Factors, 
decreased in TRAP1-silenced cells. 
Therefore, mRNA levels by Real Time q-PCR show an increase of TRAP1 
expression level in esiGRP78 cells. On the other hand, in siTRAP1 
modulated cells the gene expression levels of GRP78 results lower than 
control (Figure 22A, 22B). 
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Figure 20. Lucifearse assay. Expression levels of luciferase in hypoxia conditions  
                  after esiGRP78 (A) and siTRAP1 (B) in U251-HRE cell line, respect to   
                  control (*/**, P<0.005) 
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Figure 21. Immunoblot for HIF1α, GRP78 (A) and TRAP1 (B) and                   
                  βTUBULIN expression in U251 modulated cells in hypoxia conditions 
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Figure 22. Real Time q-PCR analysis of TRAP1 (A) and GRP78 (B)                    
                  expression in glioma cell line (U251-HRE) silenced for GRP78 and  
                  TRAP1 
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4.5 Treatment of GBM  organotypic cultures with drugs induces              
      GRP78 depletion expression 
For ex vivo experiments we used patient-derived from organotypic glioma 
cultures which preserve the tri-dimensional tissue architecture and cellular 
heterogeneity of the original tumor. They were cultured through two 
pharmacological approaches. Temozolomide (TMZ) is the current gold 
standard in chemotherapy of GBM. It is an alkylating agent that, in an 
aqueous solution at physiological pH, dissolves into its bioactive form MTIC 
(5-(3-methyl-1-triazeno)imidazole-4-carboxamide), which is capable of 
penetrating the blood-brain barrier. Gamitrinibs (GA mitochondrial matrix 
inhibitors), are small molecules designed to disrupt the HSP90 network 
compartmentalized in tumor mitochondria. Gamitrinibs consist of 3 main 
parts, including a benzoquinone ansamycin backbone of 17-AAG, a linker 
region, and 1–4 tandem repeats of cyclic guanidinium (Gamitrinib-G1–G4) 
or triphenylphosphonium (Gamitrinib-TPP). Gamitrinibs are expected to 
interact with the HSP90 ATPase pocket via the 17-AAG component, 
whereas the guanidinium and triphenylphosphonium regions are 
responsible for mitochondrial penetration. 
Globally, the expression of GRP78 decreased after treatment with high 
concentration of  TMZ (100 µM, 200 µM), respect to control (Figure 23A).  
We also evaluated the expression of hypoxia transcription factor (HIF1α), 
which results in a significantly decreased in treated sample respect to 
control (Figure 23B). 
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Figure 23. A) Real Time q-PCR analysis of GRP78 in human gliomas                 
                  samples after treatment with Temozolomide. B) Real Time q-PCR   
                  analysis of HIF1α in human gliomas samples after treatment with  
                  Temozolomide 
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As regards the treatment with TMZ data were confirmed even in 
immunohistochemistry as shown in the figure 24. Moreover, the expression 
of GRP78 and proliferation index were evaluated also by 
immunohistochemistry after treatments with GAM. As shown in figure 25, 
the expression levels of GRP78 appear increased respect to control in 
human glioma samples. 
The proliferation index (Ki67) was evaluated after treatments by two drugs, 
TMZ (100 µM, 200 µM), and GAM (10 µM, 25 µM). Globally, all treatment 
regimens caused a decreased in cell proliferation. To determined induction 
of programmed cell death we used cleaved caspase 3 (Cl-casp3). As 
shown in figure 26, apoptotic cells increased after treatment with low and 
high dosage respectively, of TMZ and GAM respect to controls (Figure 26A, 
26B). Moreover, a limited modulation of pAKT and mTOR suggests the 
absence of autophagy (Figure 27). 
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Figure 24. Immunohistochemistry analysis of Ki67 and Cleaved-Casp3 in                  
                  human gliomas samples after treatment with TMZ 
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Figure 25. Immunohistochemistry analysis of Ki67 and GRP78 in human                   
                  gliomas samples after treatment with GAM 
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Figure 26. A) Percentage of positive cells analyzed for Ki67 and Cleaved-Casp3  
                  in human gliomas samples after treatment with Temozolomide. B)  
                  Percentage of positive cells analyzed for Ki67 and Cleaved-Casp3 in  
                  human gliomas samples after treatment with Gamitrinibs   
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Figure 27. Percentage of positive cells analyzed for pAKT1 and p-mTOR                   
                   in human gliomas samples after treatment with Gamitrinibs 
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5. DISCUSSION 
Gliomas are the most common and lethal malignant tumor of the central 
nervous system representing 1.3% of all cancers. Survival rates for gliomas 
are poor, at around 12–13% for males, and 15% for females, with a median 
survival time of 14.6 months. 
Survival rates differ depending on the grade of gliomas, with low grade 
glioma having the highest survival rate [126].  
While diffused astrocytomas are the most common primary brain tumours, 
glioblastoma (GBM) is the most malignant. 
Glioblastoma (GBM, WHO grade IV) is the most common astrocytic-derived 
brain tumor in adults, more frequent in older patients (mean age 55 years). 
It is characterized by an intrinsic heterogeneity among cell types comprising 
the tumor mass. It is characterized by a highly aggressive behavior and 
poor prognosis. Despite aggressive treatments including surgical resection, 
chemo- and radiotherapy, GBM remains an incurable disease that almost 
invariably leads to neurological demise and death. Due to its high degree of 
invasiveness, radical resection of the primary tumor mass is not curative. 
Infiltrating tumor cells invariably remain within the surrounding brain, 
leading to disease progression or recurrence, either locally or distant from 
primary tumor [37]. 
Due to its aggressiveness, together with inadequate therapeutic options, 
several molecular targets are being studied to find more efficient treatments 
or as prognostic biomarkers useful for patients’ management. 
A hallmark of GBM is the presence of tumor necrotic foci surrounded by 
severely hypoxic pseudopalisading cells [127].  
Hypoxia has been show to fuel tumor cell migration [35], and to sustain the 
cancer-initiating cells niche [77]. 
Autophagy and the Unfolded Protein Response (UPR) are two 
interconnected pathways exploited by tumor cells to cope with low nutrient 
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conditions, hypoxia or other microenvironment-generated stress. Moreover, 
deregulation of these pathways contributes to neurodegenerative disorders  
Besides their recognized role of master regulators of cell homeostasis, 
subcellular compartmentalized chaperones recently emerged as novel 
promising targets for anti-cancer therapy [128], also in animal models of 
gliomas [129].  
Indeed, specific targeting of mitochondrial HSP90 induced selective cell 
killing of cancer cells [130], prevented primary and metastatic prostate 
cancer growth in vivo [104] and depletion of the endoplasmic reticulum 
chaperone GRP78 delayed glioma cell growth in vivo. GRP78 networks 
have also been uncovered, adding complexity to the molecular network that 
underpins stress responses in human cancer. 
Heat shock proteins (HSPs) are highly conserved proteins that are 
expressed in response to various forms of stress, in response to 
environmental challenges, and in specific stages of development transitions 
and differentiation. Some HSPs are also expressed under non-stress 
conditions and act as molecular chaperones. Thus, HSPs fulfill a variety of 
biologic functions, including the regulation of synthesis, folding, assembly, 
and degradation of different proteins. HSPs are constitutively expressed in 
human carcinomas or cancer cell lines of various histogenetic origins. 
Malignant gliomas are highly aggressive neoplasms that are rather 
resistant to radiotherapy and chemotherapy. Preliminary observations 
indicated HSPs expression in glioma cell lines, but have also been reported 
to express several HSPs in vivo, including members of the small HSPs 
family, as well as HSP90. The high expression of HSPs in malignant glioma 
indicates a possible role of these proteins in resistance to cancer 
chemotherapy. This is because HSPs protect cells from many cell-
damaging agents or conditions of environmental stress [131].             
Several studies have reported a positive correlation of HSP expression with 
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histologic tumor grade, as shown for small HSP in astrocytic tumors [132] 
and in ovarian cancer and for HSP70 in colorectal cancer and endometrial 
carcinomas [133]. Because HSP are potential factors of cancer cell 
resistance to cytoablative therapy, we studied the expression and functional 
activity of HSP in human malignant gliomas in vitro and in vivo. 
GRP78 is best known for its roles in the ER where it promotes the folding, 
maturation and assembly of nascent proteins and also coordinates the 
unfolded protein response (UPR) that alleviates ER stress [134].  
Although it is constitutively expressed, GRP78 levels increase greatly in 
response to demanding conditions such as hypoxia and nutrient deprivation 
and it has been heavily implicated in cytoprotection and chemoresistance in 
the tumor microenvironment where these conditions prevail [116]. 
The first direct evidence for the involvement of GRP78 in cancer 
progression came from the demonstration that GRP78 knockdown in 
fibrosarcoma cells using antisense prevented tumor formation in nude mice 
[135]. It was further shown that a suicide transgene driven by the GRP78 
promoter in breast cancer cells completely blocked tumor growth in mice. 
More recently, it was demonstrated that GRP78 heterozygous mice 
develop normally but are resistant to transgene-induced mammary tumor 
growth. In this study, it was demonstrated that reduced GRP78 levels in 
heterozygous mice resulted in decreased tumor cell proliferation, increased 
tumor cell apoptosis and reduced tumor angiogenesis [136,137].  
Recently, the group of Chae YC et al., demonstrated that suboptimal 
mitochondrial HSP90 targeting by Gamitrinibs (small molecules that inhibit 
ATPase activity of mitochondrial HSP90-like chaperones) impairs tumor 
bioenergetics, activates pro-survival autophagy and stimulates endoplasmic 
reticulum UPR as evidenced by GRP78 over-expression.  
Preliminary data show that GRP78 participates in cripto-mediated cell 
migration [138] and in embryonic or adult hematopoietic stem cell 
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maintenance [139]. Nevertheless, precise mechanisms that relate 
morphological features to specific molecular alterations have not been 
reported. Many recent studies converge to ask which roles, if any, cancer 
stem cells (CSCs) play in cancer pathogenesis. CSCs appear to be 
resistant to chemotherapy, suggesting that these cells persist after 
treatment and drive recurrence [59]. CSCs are defined as cells within a 
tumor that possess the capacity to self-renew and to produce the 
heterogeneous lineages of cancer cells that comprise the tumor [140].  
They share many of the characteristics of normal tissue stem cells, which 
could help to explain certain clinical features such as tumor hierarchy, 
recurrence, metastasis and therapy resistance.  
Our data are in line with the literature about GRP78 over-expression in 
brain tumors and as an indicator of poor prognosis and shorter overall 
survival. Performing immunohistochemistry for GRP78 on a glioma 
patients’ tissue microarray we could evidence a significant overexpression 
of the HSP in higher grades gliomas compared to grade II tumors or normal 
brain parenchyma. Moreover GRP78 and TRAP1 appears to be enriched in 
peri-necrotic areas of high-grade human gliomas where GRP78 
overexpression correlates with HIF-1α and Bcl2. 
Up-regulation of GRP78 seems to happen at gene expression level, since 
its mRNA was increased in an independent set of gliomas. Finally, our data 
shows that GRP78 is a poor prognostic marker for high grades gliomas. 
With advances in siRNA (small interference RNA), it is now possible to 
target important components involved in the development and progression 
of tumours. 
Invasion, and migration are key processes of tumor progression and are 
tightly linked to tumor recurrence and therapeutic resistance in different 
tumor types: siRNA silencing of GRP78 induced loss of viability of H1299 
and A549 lung cancer cells.  
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After silencing of GRP78 we set up functional assays to test whether the 
ability of invasion and migration of brain cancer cells suffer a change. For 
this purpose we used three tumor cell lines, two high-grade and one low-
grade cell type. In agreement with the literature decreased cell viability and 
motility could be detected in GRP78-silenced cells, whereas a non-
targeting silencing had no effect.  
Cells with tumorigenic potential, and which have a self-renewing stem cell-
like phenotype are defined cancer stem cells (CSCs). They have been 
identified in GBM, and many other tumors, are considered able to initiate 
tumor formation with fewer cells and specially, are responsible to 
chemotherapeutic agents resistant to therapy.  
To isolated the side population (SP) we used the flow cytometry FACS-
sorting which identified a subset of cells with differential efflux activity of the 
fluorescent DNA binding dye Hoechst 33342. Our data confirms the 
presence of glioma stem cell niche, in fact, stem cell markers and GRP78 
results more express in SP than NSP. In GRP78 knockout percentage 
share of SP cells was decreased compared to the control non-transfected. 
As well know heat shock proteins (HSPs) are involved in protein folding, 
aggregation, transport and/or stabilization by acting as a molecular 
chaperone, leading to inhibition of apoptosis by both caspase dependent 
and/or independent pathways. HSP70 and HSP90 are known to suppress 
apoptosis by directly associating with Apaf-1 and blocking the assembly of 
pro-caspase 9. In line with the literature our studies on apoptosis showed 
that GRP78 knockout was associated to an increase in the apoptotic 
fraction of glioma cells compared to control transfected cultures.  
Hypoxia is considered to play a crucial role in tumor development and 
progression and to be a main factor in GBM, promoting angiogenesis, 
tumor invasiveness, loss of apoptotic potential, genomic instability, and 
chemotherapy and radiation resistance. For these reasons, hypoxia is 
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considered a promising target for the treatment of many different human 
cancers usually characterized by the presence of extensive hypoxic and 
necrotic areas, GBM in particular. In this context, to target HSP90-GRP78-
HIF1α axe, we have induced a condition with low level of oxygen and we 
evaluated protein expression level in cell lines silenced for GRP78 and 
TRAP1. The results indicated a relationship between GRP78-TRAP1-
HIF1α. In fact, in TRAP1-silenced cells, the expression level of 
GRP78/HIF1α appear decreased. Oppositely, the depletion of GRP78 
appears to activate a compensatory pathway inducing the expression of 
TRAP1/HIF1α. Hypoxia and especially the oxygenation-dependent 
transcription factor, HIF-1, could be valid targets for the development of 
new cancer therapies. 
Ex vivo culture of human gliomas tissues were provided experimental 
evidence for novel drugs combination strategies to inhibit glioma growth 
and dissemination.  
Cancer cell ability to survive and invade extracellular matrix were provided 
preliminary evidence of therapeutic efficacy in preventing tumor ability to 
spread and recur. Indeed, the limitations imposed by the blood-brain barrier 
to obtain reliable serological markers from glioma patients is overcome in 
this study by the use of ex vivo tissue cultures of human glioma tumors. 
In ex vivo, the organotypic glioma tissue were treated with two different 
pharmacological approaches. Globally, the expression of GRP78 
decreased after treatment with TMZ respect to control.  Also the expression 
of hypoxia transcription factor, results in a significantly decreased in treated 
sample respect to control. Therefore, all treatment regimens caused a 
decreased in cell density and an induction of programmed cell death. 
Treatments with GAM, oppositely induced pro-survival autophagy with over 
expression of GRP78. 
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6. CONCLUSIONS 
GBM is the most common and lethal primary malignancy of the CNS. Even 
with surgical resection and aggressive treatment with chemo- and 
radiotherapy, the prognosis remains very poor. Due to continued 
advancements, the understanding of the complex biology of GBM and its 
pathogenesis, a wide variety of novel therapeutic approaches have been 
developed and are currently under study as potential treatments for GBM. 
Despite promising results in preclinical trials, many of these therapies have 
provided limited or no therapeutic efficacy in human clinical trials. Thus, 
although survival of patients with GBM continues to slowly improve, 
treatment of GBM remains extremely challenging. Continued research and 
development of new molecular targeted and immunotherapeutic 
approaches, based on a detailed understanding of molecular pathogenesis, 
can reasonably be expected to lead to increased survival and more 
favorable prognosis of patients with GBM. 
HSPs are highly conserved proteins that have an important cellular function 
as molecular chaperones, protecting cells from various forms of stress. 
Further, the HSP family has been classified as a potential class of 
antiapoptotic genes that can down-regulate caspase activity, thus being 
important mediators of resistance to diverse apoptotic stimuli. 
In the light of these evidences, the aim of this project were investigate 
GRP78-HSP90 axe expression in glioma, to understand which is their role 
in malignant brain cancer. 
Different experimental approaches used in our research, highlighted that, 
high levels of GRP78 are characteristic of GBM and could influence the 
chemoresistance typical of high grades gliomas, indeed patients with a low 
GRP78 expression had a longer OS. 
This results emphasizes from the molecular point of view the importance of 
the GRP78 as a poor prognostic marker for high grades gliomas and also, 
as HSPs are enriched in peri-necrotic tumor areas sustaining a pro-survival 
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environment. Moreover, these data suggest that GRP78 over-expression in 
brain tumors could sustain the stem cell population in stress conditions 
such as hypoxia. 
Despite increased understanding of the molecular alterations that 
characterize different subsets of high-grade glioma, this tumor remain a 
fatal disease with inadequate treatment options. Therefore, there is a 
crucial need to identify proteins that could be effectively targeted the cancer 
cells. We have demonstrated that GAM could be an innovative and 
promising drug. This approach could provide fundamental evidences of a 
novel therapeutic strategy for GBM, to hamper disease recurrence, and 
potential markers to predict therapeutic efficacy, thereby improving 
prognosis of glioma patients. 
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